Arrowhead Corp (ARWR) - מקדם חוב לטווח ארוך להון

Arrowhead Pharmaceuticals (ARWR) generates revenue through royalties and licensing fees from global pharma behemoths for access to its unique technologies. The company invests heavily in R&D to create systems for the targeted suppression of pathological genes. This price chart on the GURU.Markets platform, where the metric stands at 2.88, reflects the dynamics of a business developing revolutionary liver treatments by "switching off" diseases at the genetic level.

Leveraging an organic growth strategy and licensing agreements with pharma behemoths, the current long-term debt-to-equity ratio reflects the financial stability of Arrowhead Pharmaceuticals (ARWR). This metric compares obligations with maturities exceeding one year against shareholders' equity, allowing investors to assess the degree of leverage: low values confirm a conservative approach to funding R&D without the risk of excessive credit burden.